Research
Hormonal
GLP-1 RAs reduce Major Adverse Cardiovascular Events (MACE) by 14-20% in patients with Type 2 Diabetes and Obesity, independent of glycemic control.
GLP-1 medications significantly reduce the risk of heart attacks, strokes, and cardiovascular death in people with diabetes or obesity. This benefit exists even if blood sugar control is not the primary goal. Discuss cardiovascular risk with your doctor to see if a GLP-1 RA is appropriate.
StrongSupportsHIGH confidence
Established applications demonstrate robust efficacy in... cardiovascular protection (14–20% reduction in major adverse cardiovascular events, or MACE).
Why this rating
Based on large-scale cardiovascular outcome trials (SELECT, LEADER, SUSTAIN-6, etc.).
Source
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Shikha Patel et al. · Pharmaceutics · 2025
DOI 10.3390/pharmaceutics17081036
Meta-analysisCited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) produce significant weight loss (7–24%) and HbA1c reductions (1.5–2.0%) through pleiotropic mechanisms including enhanced mitochondrial function, anti-inflammatory actions, and improved cellular quality control.Strong
- GLP-1 RAs show therapeutic potential in neurological disorders, including Alzheimer's and Parkinson's disease, by reducing amyloid-β/tau pathology, neuroinflammation, and promoting neuronal survival.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →